🇺🇸 US Stock Screener ← Switch market ⚡ HerAI

AIM ImmunoTech Inc. AIM PHARMA

Healthcare · Biotechnology · United States
Financial distress score 77/100 (Very weak) — see indicators →
https://aimimmuno.com
Company Profile ↓
$0.16
-93.96% 1Y
Mkt Cap$6.38M
P/E-0.05
P/B0.67
52W High$2.79
52W Low$0.16
Book Value$0.27
EPS (TTM)$-2.98

Company Overview

AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts. It is also developing Ampligen for potential treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was founded in 1966 and is headquartered in Ocala, Florida.

Recent Developments

  • Dec 2025 Revenue of $88.00K (-48.2% YoY); net profit $-13.96M.
  • Trailing 12 Months Year-on-year growth — revenue +4.0%.
  • 5-Year Trend Long-term compounding — revenue CAGR -14.5%, profit CAGR 9.4%.

Growth & Price Performance

Compounded Sales Growth

5 Years:-14.54%
1 Year:4.00%

Compounded Profit Growth

5 Years:9.41%
1 Year:-

Stock Price Performance

1 Year:-93.96%
6 Months:-69.94%
3 Months:-37.48%
1 Month:-21.85%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish
52-Week Range 0% of range
$0.16 $2.79
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMABelow
  • RSI (14)34.35 · Neutral
Price Performance
1M-21.85%
3M-37.48%
6M-69.94%
1Y-93.96%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

No notable strengths flagged.

CONS

  • Revenue declined at -14.5% CAGR over 5 years.
  • Trading 94.4% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-0.05
Industry PE
25.45
Forward P/E
-0.43
PEG Ratio
0.71
Book Value
$0.27
Price to Book
0.67
P/S
75.59
EV/EBITDA
0.04
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
-14.54%
Profit 5Y
9.41%
Revenue (YoY)
4.00%
Earnings (YoY)
-

Profitability & Returns

ROCE
-
ROE
-
ROA
-82.58%
Profit Margin
0.00%
Op Margin
-
Gross Margin
-23.16%
EPS (Latest Qtr)
$-0.43
EPS (TTM)
$-2.98

Balance Sheet & Liquidity

Debt/Equity
0.51
Quick Ratio
2.02
Current Ratio
2.11
Debt
$3.92M
Total Assets
$12.73M
Current Assets
$6.21M
Working Capital
$-2.93M

Ownership

Promoter Holding
0.51%
Chg in Prom Hold
-0.23%
FII / Inst Holding
2.88%
Chg in FII Hold
-1.00%

Financial Snapshot

Enterprise Value
$6.38M
Total Revenue (TTM)
$95.00K
EBITDA
$-10.73M
Free Cash Flow
$-14.06M
Operating Cash Flow
$-14.37M
Shares Outstanding
39.89M
Gross Margin
-23.16%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 AIM AIM ImmunoTech Inc. PHARMA 0.16 -0.05 $6.38M 0.00% - - -14.54% 9.41%
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,273.46 42.83 $1.14T 0.60% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 263.81 30.60 $635.76B 1.98% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 285.64 80.69 $504.76B 2.54% 10.47% -129.24% 1.75% -29.06%
5 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 418.09 26.85 $375.28B 2.47% 9.74% 14.15% 10.40% 5.43%
6 MRK Merck & Co., Inc. SPXR3KPHARMA 145.27 116.22 $358.41B 2.31% - 6.96% 5.64% 10.01%
7 NVS Novartis AG PHARMA 151.12 22.83 $287.24B 3.36% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 171.49 25.63 $265.96B 2.00% 15.97% 21.96% 9.82% 45.96%
9 TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA 673.82 36.30 $249.14B 0.29% 8.14% 13.51% 8.81% 12.95%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Mar 2014Jun 2014Sep 2014Mar 2015Jun 2015Sep 2015Mar 2016Jun 2016Sep 2016Mar 2017Jun 2017Sep 2017Mar 2018Jun 2018Sep 2018Mar 2019Jun 2019Sep 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue ------------56.00K33.00K38.00K-29.00K61.00K45.00K40.00K36.00K28.00K23.00K33.00K33.00K30.00K21.00K49.00K42.00K46.00K40.00K50.00K35.00K-16.00K25.00K26.00K21.00K22.00K26.00K
Cost of Revenue ----------------------------------10.00K10.00K68.00K40.00K4.00K-
Gross Profit ----------------------------------6.00K15.00K-42.00K-19.00K18.00K-
Operating Expenses ----------------------------------3.62M2.66M2.40M2.93M2.24M-
Operating Income -5.11M-5.08M-4.33M-4.92M-4.90M-3.98M-3.68M-2.81M-3.23M-3.24M-2.73M-2.65M-2.57M-3.23M-3.04M-2.93M-3.22M-3.21M-3.33M-3.34M-3.35M-3.75M-3.72M-3.93M-3.15M-4.70M-6.52M-4.29M-5.46M-8.16M-5.73M-3.69M-4.49M--3.62M-2.65M-2.45M-2.95M-2.23M-3.51M
EBITDA -----------------------------------3.52M-2.59M-3.08M-3.74M-2.68M-
Interest Expense ----------------------------------124.00K149.00K148.00K391.00K304.00K-
Pretax Income -----------------------------------3.71M-2.79M-3.28M-4.17M-3.02M-
Tax Provision ----------------------------------------
Net Income ----3.44M-4.84M-3.80M-2.16M-1.30M-2.86M-2.82M-2.19M-1.25M-2.71M-2.42M-3.08M-3.37M-2.04M-2.95M-3.81M-3.37M-3.31M-3.58M-5.88M-3.83M-3.82M-4.85M-6.38M-3.66M-4.91M-7.82M-5.82M-1.84M-3.70M--3.71M-2.79M-3.28M-4.17M-3.02M-3.79M
Diluted EPS --------------------------0.10-0.13-0.08-0.10-0.16-0.12-3.00-6.00--5.00-3.68-1.57--0.69-0.43
R&D Expense 2.33M2.33M1.89M2.67M2.44M1.97M1.00M900.00K1.34M1.39M1.11M787.00K855.00K1.34M1.59M928.00K1.10M1.19M898.00K1.46M1.10M1.42M1.32M2.01M1.04M2.48M1.37M2.05M2.95M2.73M1.95M1.15M1.44M-1.08M1.17M607.00K-482.00K589.00K

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 111.00K135.00K161.00K213.00K150.00K197.00K133.00K92.00K437.00K367.00K140.00K163.00K-141.00K202.00K170.00K88.00K
Cost of Revenue -------------042.00K31.00K128.00K
Gross Profit -------------141.00K160.00K139.00K-40.00K
Operating Expenses -------------20.06M32.08M19.91M11.62M
Operating Income -13.26M-16.39M-14.29M-20.34M-17.17M-19.10M-16.65M-13.80M-11.42M-11.50M-12.44M-15.15M--19.92M-31.92M-19.77M-11.66M
EBITDA --------------19.67M-28.72M-16.49M-12.94M
Interest Expense -------------00585.00K812.00K
Pretax Income --------------19.45M-28.96M-17.32M-13.96M
Tax Provision -----------------
Net Income -----16.23M-17.45M-15.23M-7.50M-8.26M-9.83M-9.40M-14.40M--19.45M-28.96M-17.32M-13.96M
Diluted EPS --------------39.96-59.94-30.92-8.62
R&D Expense 7.00M7.61M6.72M9.51M8.36M8.99M8.04M5.11M4.10M4.78M4.65M5.72M7.67M6.99M10.94M6.20M3.92M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Sep 2019Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --51.68M43.51M57.70M31.87M29.44M22.80M18.87M14.21M13.85M-20.75M64.58M-40.49M19.38M8.61M5.78M
Current Assets ---------------36.32M14.56M4.18M3.29M
Cash & Equivalents 6.12M58.07M2.92M3.10M2.21M803.00K2.16M2.12M2.41M1.41M299.00K-1.47M38.50M-27.05M5.44M1.70M2.98M
Inventory -------------------
Receivables --------------1.64M1.68M---
Total Liabilities --5.73M5.55M13.00M2.57M4.44M--------2.02M9.15M9.93M15.56M
Current Liabilities --2.83M5.07M12.65M2.53M4.44M2.43M2.44M2.71M5.29M-1.13M1.10M-1.36M8.65M9.54M6.22M
Long Term Debt ----------2.32M-2.10M1.88M----927.00K
Total Debt ---------------837.00K718.00K2.94M4.90M
Total Equity 11.54M58.70M45.95M37.97M44.70M29.30M25.00M20.37M15.50M8.70M5.58M13.44M13.44M61.29M-38.47M10.23M-1.32M-9.78M
Shares Outstanding ---------------481.32K491.51K655.92K3.07M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -9.30M-11.89M-10.10M-13.14M-16.83M-13.96M-16.05M-7.38M-7.94M-10.64M-9.07M-10.37M--16.11M-21.27M-14.89M-10.96M
Investing Cash Flow -574.00K-43.52M8.65M-16.07M22.27M2.53M6.35M2.92M2.73M92.00K-6.15M-9.16M-10.99M-832.00K4.71M1.85M
Financing Cash Flow 61.82M250.00K1.62M28.31M-6.85M12.79M9.66M4.76M4.21M9.44M16.39M56.56M-80.00K485.00K6.44M10.39M
Capital Expenditure -332.00K-729.00K-1.80M-5.75M-898.00K-504.00K-240.00K-160.00K-20.00K-51.00K-68.00K-22.00K--271.00K-585.00K-556.00K-378.00K
Free Cash Flow -9.63M-12.62M-11.90M-18.89M-17.73M-14.47M-16.29M-7.54M-7.96M-10.69M-9.13M-10.39M--16.38M-21.85M-15.44M-11.34M
Net Change in Cash --------------5.04M-21.61M-3.74M1.28M

Ratios (Annual)

Figures in %.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % -------------100.0%79.2%81.8%-45.5%
Operating Margin % -11,949.5%-12,138.5%-8,878.9%-9,549.3%-11,444.7%-9,694.9%-12,518.8%-15,004.3%-2,612.4%-3,132.4%-8,887.9%-9,295.7%--14,129.8%-15,800.0%-11,630.6%-13,254.5%
Net Margin % -----10,816.7%-8,857.9%-11,451.1%-8,154.3%-1,889.9%-2,677.7%-6,717.1%-8,834.4%--13,790.8%-14,337.6%-10,188.2%-15,861.4%
ROE % -----55.4%-69.8%-74.8%-48.4%-94.9%-176.1%-70.0%-23.5%--50.5%-283.0%1,310.1%142.7%
ROCE % --33.5%-37.2%-45.1%-58.5%-76.4%-81.7%-84.0%-99.3%-134.4%-63.4%-23.9%--50.9%-297.5%2,132.9%2,638.9%

Shareholding Pattern

Insiders
0.51%
Institutions
2.88%
Public Float
2.89%

Top Institutional Holders

#Holder% HeldSharesValue
1 Jane Street Group, LLC 1.06% 807.88K $145.42K
2 Virtu Financial LLC 0.16% 124.27K $22.37K
3 Morgan Stanley 0.07% 50.86K $9.15K
4 Geode Capital Management, LLC 0.06% 46.00K $8.28K
5 UBS Group AG 0.04% 28.93K $5.21K
6 Goldman Sachs Group Inc 0.04% 32.44K $5.84K
7 Susquehanna International Group, LLP 0.03% 21.86K $3.93K
8 Ground Swell Capital, LLC 0.02% 12.22K $2.20K
9 Vanguard Fiduciary Trust Co 0.02% 17.52K $3.15K
10 Tower Research Capital LLC (TRC) 0.01% 4.67K $840

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for AIM

Yahoo Finance Wed, 07 Oct 2026

AIM ImmunoTech’s Strategy to Address Immune Resistance in Pancreatic Cancer Featured in BioTuesdays

CEO interview explores Ampligen’s potential to extend survival and improve quality of life as AIM advances toward pivotal development Access the article here OCALA, Fla., Oct. 07, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American:…

Yahoo Finance Mon, 05 Oct 2026

AIM ImmunoTech Highlights Recent Media Coverage of Ampligen’s® Broad-Spectrum Antiviral and Biodefense Potential

OCALA, Fla., Oct. 05, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today highlighted recent media coverage of the antiviral potential of Ampligen® (rintatolimod), the Company’s investigational d…

Yahoo Finance Wed, 30 Sep 2026

AIM ImmunoTech Discusses Ampligen®’s Potential to Complement Emerging Pancreatic Cancer Therapies in New CEO Corner Video

Company highlights supportive survival observations, potential for biomarker-driven patient selection and upcoming Phase 2 DURIPANC milestones Access it here OCALA, Fla., Sept. 30, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American…

Yahoo Finance ue, 22 Sep 2026

AIM ImmunoTech Highlights Ampligen’s Potential Role in the Evolving Pancreatic Cancer Treatment Landscape Following FDA Approval of Revolution Medicines’ Daraxonrasib

Company CEO outlines the differentiated mechanism and clinical potential of Ampligen in pancreatic cancer Survival data highlighted in accompanying chart show Ampligen-associated median overall survival of 34.8 months in a selected pancreat…

Yahoo Finance Wed, 09 Sep 2026

AIM ImmunoTech Highlights Scientific Rationale, Supportive Data and Continued Advancement of Ampligen® in Pancreatic Cancer in New CEO Corner Video

Company continues to advance Phase 2 DURIPANC study and broader clinical strategy evaluating Ampligen’s potential to reshape the tumor microenvironment and enhance checkpoint inhibition Access it here OCALA, Fla., Sept. 09, 2026 (GLOBE NEWS…

Yahoo Finance hu, 27 Aug 2026

AIM ImmunoTech Participates in the Virtual Investor ‘Why Now’ On-Demand Conference

Video webcast now available here OCALA, Fla., Aug. 27, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that it participated in the Virtual Investor "Why Now" on-demand conference. D…

AIM — Frequently Asked Questions

What is the current share price of AIM ImmunoTech Inc. (AIM)?

As of 2026-10-23 16:27 PDT, AIM ImmunoTech Inc. (AIM) trades at $0.16 on NYSE American. Its 52-week range is $0.16 to $2.79.

What is the market capitalisation of AIM?

AIM ImmunoTech Inc. (AIM) has a market capitalisation of $6.38M on NYSE American.

What is the P/E ratio of AIM?

AIM trades at a trailing price-to-earnings (P/E) ratio of -0.05. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 0.67.

Is AIM a good stock to buy?

This page provides a data-driven analysis of AIM ImmunoTech Inc. (AIM), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space